Riverain Technologies’ FDA-cleared ClearRead™ Chest suite is available through the Rapid Enterprise™ Platform, alongside a full-body portfolio of deep clinical AI within a consistent, connected workflow. Designed for chest CTs and X-rays, ClearRead Chest helps radiologists detect, characterize and visualize pulmonary nodules, pneumothoraces and coronary artery calcifications.
The integration brings Riverain’s chest imaging AI together with RapidAI’s full-body deep clinical AI portfolio of more than 50 clinical solutions, all in a connected, consistent workflow.
Subtle chest findings can be difficult to see, laborious to measure, and time-consuming to compare. Riverain’s patented vessel and bone suppression technology helps reveal pulmonary nodules and other lung pathology, supporting more confident interpretation and helping ease radiologists’ cognitive burden. Advanced capabilities quantify, characterize, and compare prior findings, then summarizing into draft radiology reports.
ClearRead Chest complements RapidAI’s broader clinical AI portfolio, expanding the tools teams can access through the platform to meet their patients’ needs.
The integration will bring ClearRead Chest into the RapidAI environment:
Rapid Edge Cloud™ provides enterprise infrastructure for secure deployment and integration with existing systems.
Rapid Navigator Pro™ connects the tools to radiologists’ workflows.
Automated measurements integrated into your reports.
By integrating with existing PACS, EHR and reporting systems, the platform is designed to help health systems add clinical capabilities while maintaining a consistent experience across sites.
Expanding your AI capabilities should build on the systems and workflows your teams already rely on. With ClearRead Chest, we’re continuing to give your teams more of the clinical AI they need, with the workflows they know and the infrastructure you trust.
Read Riverain’s full announcement